We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 28, 2020

R-FND Followed by Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance in Untreated High-Risk Follicular Lymphoma

Leukemia and Lymphoma

 

Additional Info

Disclosure statements are available on the authors' profiles:

Leukemia and Lymphoma
Initial Report of a Phase II Study With R-FND Followed by Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance in Patients With Untreated High-Risk Follicular Lymphoma
Leukemia and Lymphoma 2020 Sep 14;[EPub Ahead of Print], F Samaniego, P McLaughlin, SS Neelapu, L Feng, M Fanale, L Nastoupil, MA Rodriguez, B Pro, E Taylor, FB Hagemeister, N Fowler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading